Edition:
United States

Apollo Endosurgery Inc (APEN.OQ)

APEN.OQ on NASDAQ Stock Exchange Global Market

6.54USD
18 May 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$6.54
Open
$6.44
Day's High
$6.55
Day's Low
$6.01
Volume
4,178
Avg. Vol
7,342
52-wk High
$8.25
52-wk Low
$3.60

Chart for

About

Apollo Endosurgery, Inc., formerly Lpath, Inc., is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company's device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80... (more)

Overall

Beta: 0.42
Market Cap(Mil.): $114.51
Shares Outstanding(Mil.): 17.51
Dividend: --
Yield (%): --

Financials

  APEN.OQ Industry Sector
P/E (TTM): -- 39.22 32.53
EPS (TTM): -1.85 -- --
ROI: -38.24 14.34 12.63
ROE: -71.33 17.22 14.50

BRIEF-Apollo Endosurgery Q4 Loss Per Share $0.42

* APOLLO ENDOSURGERY, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS

Mar 01 2018

BRIEF-Apollo Endosurgery Announces MFDS Approval For Orbera Intragastric Balloon System

* APOLLO ENDOSURGERY ANNOUNCES MFDS APPROVAL FOR ORBERA INTRAGASTRIC BALLOON SYSTEM IN SOUTH KOREA, A NON-SURGICAL SOLUTION TO ASSIST PATIENTS WITH WEIGHT LOSS Source text for Eikon: Further company coverage:

Feb 22 2018

BRIEF-Apollo Endosurgery Inc Files For Stock Shelf Of Upto $50 Million - SEC Filing ‍​

* APOLLO ENDOSURGERY INC FILES FOR STOCK SHELF OF UPTO $50 MILLION - SEC FILING ‍​ Source text (http://bit.ly/2AONduG) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Dec 04 2017

BRIEF-Apollo Endosurgery Receives FDA Clearance For Overstitch Sx Endoscopic Suturing System

* APOLLO ENDOSURGERY RECEIVES FDA CLEARANCE FOR OVERSTITCH™ SX ENDOSCOPIC SUTURING SYSTEM

Nov 27 2017

Earnings vs. Estimates